未登录

K

Kae Hashimoto

Department of Obstetrics and Gynecology

H指数:29

被引数:2,696

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Guideline-concordant treatment and clinical outcomes in older patients with endometrial cancer in Japan: a retrospective single-institution study

日本子宫内膜癌老年患者指南一致性治疗与临床结局：一项回顾性单中心研究

International Journal of Clinical Oncology

IF2.8

2026-07-230

OA

Relative survival of large-cell to small-cell neuroendocrine carcinoma of the uterine cervix

大细胞与小细胞子宫颈神经内分泌癌的相对生存率

International Journal of Gynecological Cancer

IF4.7

2025-12-050

PRE

Clinical and pathological characteristics and outcomes of small cell neuroendocrine carcinoma of the uterine cervix

子宫颈小细胞神经内分泌癌的临床与病理特征及预后

International Journal of Gynecological Cancer

IF4.7

2025-07-110

PRE

Ovarian cancer predisposes neutrophils to form neutrophil extracellular traps(NETs)

CANCER RESEARCH

IF16.6

2024-03-220

PRE

A patient-derived xenograft (PDX) orthotopic mouse model of rare gynecologic mesonephric-like adenocarcinoma as a platform of personalized medicine

CANCER RESEARCH

IF16.6

2024-03-041

PRE

Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation

MOLECULAR CANCER RESEARCH

IF4.7

2023-06-165

OA

Sleeping Beauty Transposon Mutagenesis Identifies Genes Driving the Initiation and Metastasis of Uterine Leiomyosarcoma

CANCER RESEARCH

IF16.6

2021-09-026

OA

Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer

MOLECULAR CANCER RESEARCH

IF4.7

2021-05-2058

OA

Prognostic significance of bone marrow FDG uptake in patients with gynecological cancer

SCIENTIFIC REPORTS

IF3.9

2021-01-2621

OAAI

Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells

SCIENTIFIC REPORTS

IF3.9

2020-10-0715

OAAI

The role of myeloid-derived suppressor cells in endometrial cancer displaying systemic inflammatory response: clinical and preclinical investigations

IF6.3

2019-09-2532

OAAI

The development of a novel microRNA replacement therapy for ovarian cancer - a potential of patient derived-exosomes as a carrier

CANCER RESEARCH

IF16.6

2019-07-010

PRE

Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells

IF3.4

2018-11-05107

OAAI

Lurbinectedin (PM01183), a selective inhibitor of active transcription, effectively eliminates both cancer cells and cancer stem cells in preclinical models of uterine cervical cancer

INVESTIGATIONAL NEW DRUGS

IF2.7

2018-10-3023

PREAI

Exosomal miR-1290 is a potential of high-grade serous ovarian carcinoma and can discriminate patients from those with malignancies of other histological types

JOURNAL OF OVARIAN RESEARCH

IF4.2

2018-09-1572

OAAI

Low miR-522 expression is correlated with paclitaxel resistance in ovarian cancer cells

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Elevated level of serum miR-1290 is correlated with high-grade serous ovarian epithelial ovarian cancer and might be a potential biomarker

CANCER RESEARCH

IF16.6

2018-07-010

PRE

Sleeping Beauty transposon mutagenesis screen identifies cancer genes of uterine leiomyosarcoma driving sarcomagenesis and lung metastasis

CANCER RESEARCH

IF16.6

2018-07-010

PRE

In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IF9.1

2017-08-1592

OAAI

In vivo pooled shRNA library identifies KPNB1 as a new drug target for epithelial ovarian cancer

CANCER RESEARCH

IF16.6

2017-07-010

PRE